The Impact of Prescription Drug Price Controls: An International Policy and Patient Perspective
International pricing indexes, price setting, reference pricing, importing socialized medicine – what are their real impacts? Join us for a lunch discussion on proposed policies that just might change America’s lead on innovation and access.
Other countries frequently utilize a range of market-distorting policies to determine the cost of medicines. But what are the real impacts of importing these policies? In an effort to address the cost of medicines, the Trump administration is proposing to implement an International Reference Pricing (IPI) policy that would set the prices of certain drugs in Medicare Part B based on the prices of those drugs in other countries, namely: Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, the Netherlands, and the United Kingdom. Not only would this policy fail to address the cost of medicines, it threatens to slow the pace of innovation and restrict patients’ access to critical medical treatments.
Kent Lassman, President, Competitive Enterprise Institute
John Adams, Chair, Best Medicines Coalition and CEO, Canadian PKU and Allied Disorders
Tim Andrews, Executive Director, Taxpayers Protection Alliance and Founder, Australian Taxpayers Alliance
Jolanta Bilinska, Founder, World Patients Alliance and Director of Development, Dr. K. Jonscher City Medical Centre
Patrick Hedger, Research Fellow, Competitive Enterprise Institute
Barbara Kolm, Director and Founder, Austrian Economics Center
Wolfgang Müller, Executive Director, Institute for Free Enterprise
Andrew Spiegel, Founder and Executive Director, Global Colon Cancer Association
When: Tuesday, November 5, 2019 12:00 – 1:30 pm
Where: National Press Club, Holeman Lounge, 529 14th Street NW, Washington, DC 20045
Contact email@example.com with questions or dietary restrictions.